1
|
Mobitz H, Jahnke W, Cowan-Jacob S. Expanding the Opportunities for Modulating Kinase Targets with Allosteric Approaches. Curr Top Med Chem 2016; 17:59-70. [DOI: 10.2174/1568026616666160719165314] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2013] [Revised: 12/17/2015] [Accepted: 01/15/2016] [Indexed: 11/22/2022]
|
2
|
Zhang J, Gray NS, Sim T, Choi Y, Deng X, Adrián F, Li A, Sun F, Liu Y, Okram B, Warmuth M, Iacob R, Engen J, Powers J, Azam M, Daley G, Jahnke W, Cowan-Jacob S, Manley P. Abstract B165: Abl kinase myristate-site inhibitor, mechanism and application. Mol Cancer Ther 2009. [DOI: 10.1158/1535-7163.targ-09-b165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
We recently reported a new class of allosteric inhibitors, exemplified by GNF-2, that selectively inhibit the proliferation of Bcr-Abl dependent cells. Here we demonstrate, using selection for resistant Bcr-Abl clones, site-directed mutagenesis, affinity chromatography, and steady-state kinetics, that GNF-2 inhibits Bcr-Abl kinase activity by binding to the Abl myristate binding pocket and stabilizes the auto-inhibited conformation. We demonstrate that the 2-hydroxyethyl amide analog of GNF-2, GNF-5, in combination with ATP-competitive inhibitors such as nilotinib and dasatinib can overcome the T315I “gatekeeper” mutant of Bcr-Abl which is resistant to all clinically approved Bcr-Abl inhibitors. These studies demonstrate that targeting of the Abl myristate binding site can provide an important pharmacological means to overcome mutations that cause resistance to ATP-competitive inhibitors.
Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B165.
Collapse
Affiliation(s)
| | | | - Taebo Sim
- 1 Dana-Farber Cancer Institute, Boston, MA
| | | | | | - Francisco Adrián
- 2 Genomics Institute of the Novartis Research Foundation, San Deigo, CA
| | - Allen Li
- 2 Genomics Institute of the Novartis Research Foundation, San Deigo, CA
| | - Frank Sun
- 2 Genomics Institute of the Novartis Research Foundation, San Deigo, CA
| | - Yi Liu
- 2 Genomics Institute of the Novartis Research Foundation, San Deigo, CA
| | - Barun Okram
- 2 Genomics Institute of the Novartis Research Foundation, San Deigo, CA
| | - Markus Warmuth
- 2 Genomics Institute of the Novartis Research Foundation, San Deigo, CA
| | | | | | | | | | | | - Wolfgang Jahnke
- 5 Novartis Institutes for Biomedical Research, Basel, Switzerland
| | | | - Paul Manley
- 5 Novartis Institutes for Biomedical Research, Basel, Switzerland
| |
Collapse
|
3
|
Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94:1765-9. [PMID: 16721371 PMCID: PMC2361347 DOI: 10.1038/sj.bjc.6603170] [Citation(s) in RCA: 349] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2006] [Revised: 04/20/2006] [Accepted: 04/21/2006] [Indexed: 11/25/2022] Open
Abstract
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib inhibits the tyrosine kinase activity of the BCR-ABL protein and is an effective, frontline therapy for chronic-phase CML. However, accelerated or blast-crisis phase CML patients and Ph+ ALL patients often relapse due to drug resistance resulting from the emergence of imatinib-resistant point mutations within the BCR-ABL tyrosine kinase domain. This has stimulated the development of new kinase inhibitors that are able to over-ride resistance to imatinib. The novel, selective BCR-ABL inhibitor, AMN107, was designed to fit into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib. In addition to being more potent than imatinib (IC50< 30 nM) against wild-type BCR-ABL, AMN107 is also significantly active against 32/33 imatinib-resistant BCR-ABL mutants. In preclinical studies, AMN107 demonstrated activity in vitro and in vivo against wild-type and imatinib-resistant BCR-ABL-expressing cells. In phase I/II clinical trials, AMN107 has produced haematological and cytogenetic responses in CML patients, who either did not initially respond to imatinib or developed imatinib resistance. Dasatinib (BMS-354825), which inhibits Abl and Src family kinases, is another promising new clinical candidate for CML that has shown good efficacy in CML patients. In this review, the early characterisation and development of AMN107 is discussed, as is the current status of AMN107 in clinical trials for imatinib-resistant CML and Ph+ ALL. Future trends investigating prediction of mechanisms of resistance to AMN107, and how and where AMN107 is expected to fit into the overall picture for treatment of early-phase CML and imatinib-refractory and late-stage disease are discussed.
Collapse
Affiliation(s)
- E Weisberg
- Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
| | - P Manley
- Novartis Institutes of Biomedical Research, Basel, Switzerland
| | - J Mestan
- Novartis Institutes of Biomedical Research, Basel, Switzerland
| | - S Cowan-Jacob
- Novartis Institutes of Biomedical Research, Basel, Switzerland
| | - A Ray
- Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
| | - J D Griffin
- Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
| |
Collapse
|